Latest news with #NeulandLaboratories
Economic Times
13 hours ago
- Business
- Economic Times
Neuland Laboratories shares jump 12% ahead of final dividend
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Neuland Laboratories are trading sharply higher on Monday, up 12% at Rs 13,750 amid strong buying interest. Investors holding the stock as of the record date, July 18, 2025, will be eligible to receive a final dividend of Rs 12 per dividend payout amounts to 120% of the stock's face value of Rs 10 for the financial year ending March 31, 2025, offering shareholders a healthy the past 52 weeks, Neuland Laboratories has recorded a high of Rs 18,089.55 and a low of Rs 7,900. While the stock is currently down around 23% from its 52-week high, it continues to trade significantly above its 52-week low, reflecting underlying strength and resilience in its price stock's current 14-day Relative Strength Index (RSI) stands at 54.2. The RSI is a commonly used technical indicator that measures the strength and momentum of a stock's price below 30 generally suggest the stock may be oversold (potentially undervalued), while values above 70 indicate it may be overbought (potentially overvalued). With an RSI near the middle range, the stock is currently neither oversold or a technical standpoint, Neuland Laboratories is demonstrating a strong bullish trend. The stock is trading above all eight Simple Moving Averages (SMAs) analyzed, covering periods from short-term (5-day) to long-term (200-day). This broad-based support from multiple moving averages suggests positive momentum and a generally favorable outlook among traders.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Time of India
13 hours ago
- Business
- Time of India
Neuland Laboratories shares jump 12% ahead of final dividend
Shares of Neuland Laboratories are trading sharply higher on Monday, up 12% at Rs 13,750 amid strong buying interest. Investors holding the stock as of the record date, July 18, 2025, will be eligible to receive a final dividend of Rs 12 per share. This dividend payout amounts to 120% of the stock's face value of Rs 10 for the financial year ending March 31, 2025, offering shareholders a healthy return. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Dubai villas | search ads Get Deals Undo Over the past 52 weeks, Neuland Laboratories has recorded a high of Rs 18,089.55 and a low of Rs 7,900. While the stock is currently down around 23% from its 52-week high, it continues to trade significantly above its 52-week low, reflecting underlying strength and resilience in its price action. The stock's current 14-day Relative Strength Index (RSI) stands at 54.2. The RSI is a commonly used technical indicator that measures the strength and momentum of a stock's price movements. Values below 30 generally suggest the stock may be oversold (potentially undervalued), while values above 70 indicate it may be overbought (potentially overvalued). With an RSI near the middle range, the stock is currently neither oversold or overbought. Live Events From a technical standpoint, Neuland Laboratories is demonstrating a strong bullish trend. The stock is trading above all eight Simple Moving Averages (SMAs) analyzed, covering periods from short-term (5-day) to long-term (200-day). This broad-based support from multiple moving averages suggests positive momentum and a generally favorable outlook among traders. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
&w=3840&q=100)
Business Standard
14 hours ago
- Business
- Business Standard
Mukul Agrawal portfolio pharmaceutical stock surges 10% in weak market
Neuland Laboratories share price Shares of Neuland Laboratories rallied 10 per cent to ₹13,500 on the BSE in Monday's intra-day trade in an otherwise subdued market. In the past two trading days, the stock price of the pharmaceutical company has surged 13 per cent. In comparison, the BSE Sensex was down 0.25 per cent at 82,291 at 10:31 AM. However, thus far in the calendar year 2025, Neuland has underperformed the market by falling 6 per cent, as against 4.8 per cent rise in the benchmark index. The stock had hit a record high of ₹18,089.55 on December 4, 2024. Mukul Mahavir Agrawal holds 3.12 per cent stake in Neuland Investor Mukul Mahavir Agrawal held 400,000 equity shares or 3.12 per cent stake in Neuland at the end of March 2025 quarter, the shareholding pattern data shows. Crisil Ratings reaffirms credit rating assigned to Neuland On June 20, 2025, Crisil Ratings reaffirmed its 'Crisil A+/Stable/Crisil A1' ratings on the bank loan facilities of Neuland Laboratories. The rating agency in its rationale said that the ratings continue to reflect the established market position of Neuland in the active pharmaceutical ingredient (API) segment, its established clientele, healthy business performance, product and geographical diversification, and comfortable financial risk profile. These strengths are partially offset by susceptibility to fluctuations in raw material prices, intense competition and regulatory risks, moderate working capital requirement and vulnerability of operating margin to fluctuations in foreign exchange rates, Crisil Ratings said. The custom manufacturing services (CMS) segment is set to recover in fiscal 2026 with one molecule already commercialised and one more expected to be commercialised during the fiscal. The segmental revenue will improve with more projects expected under development. With the incremental contribution from the CMS segment and healthy continuing demand from the API segment, the operating margin is expected to recover over the medium term, Crisil Ratings said. Neuland Labs - Outlook According to the management, the revenue contribution from the CMS segment will be 55 per cent - 60 per cent over the next three-to-four years. The management highlighted that since FY25 is a year of consolidation, the company's performance moderated while maintaining flattish revenue growth on a year-on-year basis. However, management is confident upon the revenue growth trajectory in FY26 on account of the completion of additional manufacturing facilities, coupled with the scaling up of commercial molecules in the CMS segment. 'We entered FY 2025-26 with renewed momentum, underscored by the completion of additional manufacturing facilities, the anticipated commercial launch of new CMS molecules, and increasing customer interest across both generic drug substances (GDS) and CMS portfolios. These developments, along with our continued focus on operational excellence and long-term capability building, strengthen our confidence in delivering sustainable growth,' Neuland said in its FY25 annual report. The diversification away from China by Western pharmaceutical companies as they look to rebalance their supply chains is also creating fresh opportunities. Neuland said, the company is well positioned to benefit from this trend, supported by a strong reputation, high-quality infrastructure, and regulatory credibility. While tariff related developments are being closely monitored, the management does not foresee a material impact, as the company's primary competitors are based outside the US, and its position as a preferred supplier to many customers helps mitigate potential disruptions. About Neuland Laboratories Neuland is a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries. Regulated markets contributed more than 90 per cent to the group's revenue in fiscal 2025, while semi-regulated markets accounted for the rest. Geography-wise, Europe is the largest contributor (45 per cent of sales in fiscal 2025), followed by the US (41 per cent).
&w=3840&q=100)
Business Standard
28-05-2025
- Business
- Business Standard
Mukul Agrawal portfolio stock soars 30% in 2 days; zooms 99% in 18 days
ASM Technologies share price today ASM Technologies share price hit a record high today, at ₹2,644 per share on the BSE, as it rallied 18 per cent in Wednesday's intraday trade in an otherwise weak market. In the past two days, the stock price of the company, engaged in design-led manufacturing in the semiconductor and automotive industries, has zoomed 30 per cent. Since May 2, that is in the past 18 trading days, ASM Technologies shares have skyrocketed 99 per cent from a level of ₹1,330.20 which it touched on the BSE. At 10:24 AM, ASM Technologies share price was trading 9 per cent higher at ₹2,454.60 as compared to 0.24 per cent decline in the BSE Sensex. Ace Investor Mukul Mahavir Agrawal held 762,500 equity shares, representing 6.48 per cent stake in ASM Technologies, at the end of the March 2025 quarter, shareholding pattern data shows. As per the latest corporate shareholdings filed, Mukul Agrawal publicly holds 60 stocks with a net worth of over ₹6,210.6 crore, as per Mukul Agrawal held stake in Neuland Laboratories, BSE Ltd, Radico Khaitan, Nuvama Wealth Management, and PTC Industries. Strong Q4 results For the January to March 2025 quarter (Q4FY25), ASM Technologies reported consolidated profit after tax (PAT) of ₹15.35 crore on the back of strong operational performance. The company had posted net loss of ₹3.4 crore in the year-ago quarter. Revenue from operations more-than-doubled to ₹114.50 crore from ₹44.59 crore. Allotment of equity shares pursuant to conversion of warrants The company's board, on April 29, 2025, approved the allotment of 800,000 fully paid-up equity shares of face value ₹10 each at an issue price of ₹470.70 per equity share (including a premium of ₹460.70 per equity share). Sector Outlook The outlook for the Engineering Research & Development (ER&D) sector in India is optimistic, with projected growth driven by advancements in digital engineering and sustainability initiatives. By 2030, the industrial ER&D spend is expected to reach $250-280 billion, growing at a CAGR of 8-9 per cent. As per Nasscom report, key growth drivers include the increased adoption of automation, robotics, and AI-enhanced analytics. In addition, the focus on developing integrated product-service solutions is expected to contribute significantly to the sector's expansion as companies look to offer comprehensive solutions that enhance customer experience and operational efficiency, ASM Technologies had said in its FY24 annual report. There are abundant opportunities in the ER&D sector, particularly in areas like industrial IoT, digital twins, and automation. The demand for data-driven solutions drives companies to invest heavily in ER&D to optimise factory operations and improve product design through cross-functional collaboration. About ASM Technologies With over three decades of experience, ASM Technologies has been supporting customers in the areas of Engineering Design led Manufacturing. ASM has multiple delivery locations in India with a global presence in USA, Singapore, UK, Canada, Japan, Thailand and Mexico. The company's Global Delivery Model and core competencies consider the changing economic scenarios as an opportunity to provide greater value to existing clients and add new clients. The company's specific industry, domain, and technology expertise allows it to facilitate business transformation for its clients through innovative strategies and solutions.
Time of India
17-05-2025
- Business
- Time of India
Will Neuland Laboratories recover after a 7% stock drop and plummeting profits?
MUMBAI: Neuland Laboratories , one of the Dalal Street favourites in the recent bull run, tumbled almost 7% on Friday, extending losses to the third straight session, as the company's strong guidance failed to douse investor concerns over the 59% drop in its profit after tax in the fourth quarter. 'The increase in operating costs and reduced sales volumes led to Neuland shares falling today,' said Prathamesh Masdekar, research analyst, Stoxbox. ' The concern about operating costs has been ongoing since the last two quarters.' Masdekar said that while the company guided for better growth in FY26, the company's peers have reported better results and promising guidance as well. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas In Dubai | Search Ads Get Quote Undo The stock, which slumped as much as 11% during the session, closed at Rs 11,040. Last week, Neuland shares fell nearly 13%.
